Skip to main content
. Author manuscript; available in PMC: 2010 Jul 1.
Published in final edited form as: Leuk Res. 2009 Feb 20;33(7):937–947. doi: 10.1016/j.leukres.2009.01.018

Figure 1.

Figure 1

Treatment of MV4-11 and MOLM-13 cells with PFWT in combination with chemotherapeutic drugs results in an overall decrease in cell viability compared to treatment with PFWT or chemotherapeutic drug alone. MV4-11 cells were treated simultaneously (SIMT) with PFWT (μg/mL) and either 17AAG (nM) or a Flt-3 Inhibitor (nM) for 72 h or sequentially (SQT) with PFWT (μg/mL) and either cytarabine (nM) or etoposide (nM) for 72 h. In the latter case (SQT), cells were pretreated with either cytarabine or etoposide for 24 h prior to the addition of PFWT. MOLM-13 cells were treated sequentially with PFWT (μg/mL) and either 17AAG (nM), cytarabine (nM), a Flt3 inhibitor (nM) or etoposide (nM) for 72 h. For combined drug treatment of MOLM-13 cells, cells were pre-treated with individual drugs 24 h prior to the addition of PFWT. Data is a combination of at least three experiments and standard error of the mean (SEM) is represented by error bars. AraC = cytarabine; VP-16 = etoposide.